Solving the light chain mismatch of IgG-like bispecific antibody by utilizing 2A peptide based FaBody platform
Related Experiment Video
Updated: Jan 16, 2026
A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
Published on: July 12, 2018
Dong Li1,2, Pengfan Zheng2, Xuejing Yao1
1RemeGen Co., Ltd., 58 Beijing Middle Road, Yantai, 264006, Shandong, China.
Bispecific antibodies (BsAbs), engineered to target multiple antigens or epitopes simultaneously, promise enhanced therapeutic efficacy over traditional monoclonal antibodies (mAbs). However, the complex BsAbs structure presents significant production challenges, particularly chain mismatch issues. This study presents a novel approach utilizing 2A peptides within a FaBody platform to address light chain mismatches in IgG-like BsAbs. By leveraging self-cleaving 2A peptides, stable expression in mammalian cells significantly improves the accuracy of antibody chain assembly. This strategy markedly enhances the production of correctly assembled IgG-like BsAbs, providing a promising solution to critical challenges in BsAbs drug development.
Bispecific antibodies (BsAbs), engineered to target multiple antigens or epitopes simultaneously, promise enhanced therapeutic efficacy over traditional monoclonal antibodies (mAbs). However, the complex BsAbs structure presents significant production challenges, particularly chain mismatch issues. This study presents a novel approach utilizing 2A peptides within a FaBody platform to address light chain mismatches in IgG-like BsAbs. By leveraging self-cleaving 2A peptides, stable expression in mammalian cells significantly improves the accuracy of antibody chain assembly. This strategy markedly enhances the production of correctly assembled IgG-like BsAbs, providing a promising solution to critical challenges in BsAbs drug development.
